COVID-19 vaccines: Common solution, not competition

▴ COVID-19 vaccines: Common solution, not competition
After China's official approval, over a dozen countries from different continents signed purchase agreements with China for the vaccine.

At the end of 2020, one of China's self-developed COVID-19 vaccines was granted conditional approval for general use by the National Medical Products Administration. Previously, the United Arab Emirates and Bahrain had already greenlit the vaccine. After China's official approval, over a dozen countries from different continents signed purchase agreements with China for the vaccine.

Since the initial outbreak, scientists around the world have been working to develop an effective vaccine. Various approaches have been adopted, such as mRNA vaccines, inactivated vaccines, and adenovirus vector vaccines. The mRNA vaccine jointly developed by Pfizer and BioNTech was approved in the U.K. and U.S. in December 2020. The adenovirus vector vaccine developed by Oxford-AstraZeneca has not long since been rolled out. China's recently approved vaccine is inactivated, which is a mature technique, thus making it relatively safe. Without special requirements for transportation or storage, the vaccine's cost is lower, meaning it is more affordable.

Recent news on the virus mutating makes achieving herd immunity via vaccination all the more important. As such, the Chinese government has promised to provide vaccines free of charge to all Chinese people.

The approval and future use of China's inactivated vaccine has been made possible only through international cooperation. The phase 3 clinical trials, for instance, were conducted in countries including the UAE and Argentina. Now China is speeding up vaccine production, working to make them a global public good, while being more accessible and affordable. In the future, China will actively provide vaccines to developing countries, including through donations, which is in line with China's joining of COVAX.

Many foreign media outlets have continued to link vaccine development with political purposes, and have disparaged China's vaccines. In fact, research and development into COVID-19 vaccines is not a case of companies or countries competing against one another. Faced with the virus, humanity should work together to seek solutions to this common challenge.

Any effective vaccine would mark a victory for global public health and all humanity. China will continue to work with other countries on vaccine development, share knowledge and experience in fighting the pandemic, and overcome the challenge.

News report by China.org.cn on China's COVID-19 vaccines

Tags : #ChinasCovidUpdates #Covid-19Vaccine #Chinasself-developedCOVID-19vaccine #CommonSolutions #NoCompetition #COVAX #FightAgainstCovidVirus

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023
IIIT-Hyderabad among top 100 institutions for 5G Use Case LabNovember 17, 2023
Powerful, motivating and inspiring talks marked TEDx Hyderabad Women 2023 which was held with the theme "Two Steps ForwardNovember 17, 2023
Speaking the Diagnosis: How AI in Voice Analysis Is Revolutionizing Diabetes DetectionNovember 17, 2023
FDA Approves Zepbound: A New Medication for Weight Loss by Eli LillyNovember 17, 2023
CoverSelf Raises $8.2 Million in Seed Funding to Revolutionize Healthcare Claims with Innovative Fintech PlatformNovember 16, 2023
From Miracle to Medic: The Extraordinary Journey of India's First Paediatric Liver Transplant RecipientNovember 16, 2023
Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India LaunchNovember 16, 2023
Global Corporate Summit 2023 with the theme Unlocking Opportunities in a Dynamic World heldNovember 16, 2023
2nd IHub-Data Mobility Summit heldNovember 16, 2023
Revolutionary AI-powered technology detects multiple abdominal pathologies simultaneouslyNovember 16, 2023
1 Out of 3 Stroke Patients Suffer Long-Term Health Complications, Says NeurologistNovember 16, 2023
Amrita Hospital, Kochi, Launches App for People with Swallowing DifficultiesNovember 15, 2023